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Background: ESBL-producing Enterobacteriaceae (ESBLPE) are increasing in prevalence worldwide and are more
difficult to treat than non-ESBLPE. Their prevalence in the UK general population is unknown, as the only previous
UK ESBLPE faecal colonization study involved patients with diarrhoea.
Objectives: To estimate the prevalence of CTX-M ESBLPE faecal colonization in the general adult population of
England in 2014, and investigate risk factors.
Methods: A stratified random sample of 58337 registered patients from 16 general practices within four areas
of England were invited to participate by returning faeces specimens and self-completed questionnaires.
Specimens were tested for ESBLPE and carbapenemase-producing Enterobacteriaceae (CPE).
Results: 2430 individuals participated (4% of those invited). The estimated prevalence of colonization with
CTX-M ESBLPE in England was 7.3% (95% CI 5.6%–9.4%) (Shropshire 774 participants, 4.9% colonization;
Southampton City 740 participants, 9.2%; Newham 612 participants, 12.7%; Heart of Birmingham 234 individ-
uals, 16.0%) and was particularly high in: those born in Afghanistan (10 participants, 60.0% colonization, 95% CI
29.7%–84.2%); those born on the Indian subcontinent (India, Pakistan, Bangladesh or Sri Lanka) (259 partici-
pants, 25.0% colonization, 95% CI 18.5%–32.9%); travellers to South Asia (India, Pakistan, Bangladesh, Sri Lanka
or Nepal) in the last year (140 participants, 38.5% colonization, 95% CI 27.8%–50.5%); and healthcare domestics
(8 participants, unweighted 37.5% colonization, 95% CI 8.5%–75.5%). Risk factors identified included: being
born in the Indian subcontinent (aOR 5.4, 95% CI 3.0–9.7); travel to South Asia (aOR 2.9, 95% CI 1.8–4.8) or to
Africa, China, South or Central America, South East or Pacific Asia or Afghanistan (aOR 2.6, 95% CI 1.7–4.1) in the
last year; and working as a healthcare domestic (aOR 6.2, 95% CI 1.3–31). None of the 48 participants who took
co-amoxiclav in the last year was colonized with CTX-M ESBLPE. blaCTX-M-15 accounted for 66% of CTX-M ESBLPE
positives. 0.1% (two participants) were colonized with CPE.
Conclusions: CTX-M ESBLPE are established in the general population in England and prevalence is particularly high
in people from certain countries of birth or with recent travel. We recommend that these findings be taken into ac-
count in guidance on the empirical management of patients presenting with a likely Enterobacteriaceae infection.
Introduction
Extensive overuse of antibiotics worldwide has led to increasing
prevalence of antibiotic-resistant Gram-negative bacteria (mainly
Escherichia coli) that produce ESBLs; 85%–90% of these being
CTX-M genotypes.1–4 Carriage is particularly high in South Asia.4
Between 2010 and 2015 total E. coli bloodstream and urine
VC The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
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infections in England have continued to rise and, moreover, resist-
ance in E. coli to important hospital antibiotics such as co-
amoxiclav and piperacillin/tazobactam rose significantly making
treatment more difficult.5,6 ESBL-producing Enterobacteriaceae
(ESBLPE) are opportunistic pathogens with large bowel coloniza-
tion typically preceding an ESBLPE infection,7,8 so we believe that
understanding the prevalence of faecal colonization overall and
for certain sections of the general population will help inform em-
pirical antibiotic guidance. Recent European studies indicate that
travellers to countries outside Europe have an up to 10-fold higher
prevalence of ESBLPE faecal colonization than the local popula-
tion.3,9,10 The prevalence of CTX-M ESBLPE in diagnostic faecal
specimens in a UK laboratory in 2010 was double in Middle
Eastern/South Asian patients (22.8%) compared with Europeans
(8.1%).11 Studies in returning European travellers have found that
travel to South Asia was the most important risk factor,12 while
antibiotic use10,12,13 and travellers’ diarrhoea were other possible
risk factors for ESBLPE acquisition. Travel acquisition is important
as between 1% and 8% of returning travellers are hospitalized,14,15
equating to 3.1–24.8 million Europeans each year.16 Importantly,
there are no studies of the colonization of ESBLPE in the UK general
population.
This study aimed to estimate the prevalence of colonization
with CTX-M ESBLPE across different sections of the adult general
population of England in 2014, including different ethnic groups,
and to investigate the potential risk factors for their carriage.
Methods
The study was undertaken in four NHS Primary Care Trusts (PCTs) in
England. PCTs were state-funded and commissioned primary medical care
from general practices in England until 2015; this has now been taken over
by Clinical Commissioning Groups. All the UK population are registered with,
or have access to, a general medical practice whom they consult for pri-
mary care. The four PCTs were purposively selected to capture the UK ethnic
diversity: Newham (London, highest ethnic diversity), Heart of Birmingham
(predominantly Asian), Shropshire (rural, mostly white British) and
Southampton City (mixed ethnicity). Three to five willing Primary Care
Research Network practices from each PCT were non-randomly selected to
broadly represent each area with respect to ethnicity and deprivation.
Individuals aged 18 years in selected practices were stratified by re-
cord of ethnicity (white, Asian, black, other/mixed or unknown), sex and
age. Within each stratum individuals were randomly selected in 2013 and
2014 to receive an invitation letter. Respondents were sent study informa-
tion, a faeces sample collection kit (not rectal swab), £5 incentive offer and
a questionnaire (Figure S1, available as Supplementary data at JAC Online)
(including questions on age, ethnic group, country of birth, employment,
household characteristics, hospitalization, antibiotic use, travel abroad in
past year and diet). Those not returning kits received a telephone reminder.
Respondents were asked to collect scoops of faeces from both ends and
the middle of their faeces sample and place them in a sterile container,
keep the container cool and return by first-class post within 24 h to a central
laboratory. As sampling progressed, faeces returns were monitored and in-
vitations to reach Asian, black and younger age group sample sizes
increased as necessary, including direct approach by general practice re-
ceptionists to individuals in some ethnic groups. For some practices all indi-
viduals within a given stratum were invited.
Laboratory analysis
Faecal samples were screened for ESBLPE, using direct culture on selective
medium (Brilliance
TM
ESBL agar, Oxoid Ltd) for 24 h. To increase sensitivity,
all samples were enriched as well as directly plated; 20 mg of each faecal
sample was incubated for 24 h in 10 mL of brain heart infusion (BHI) broth
containing 1 mg/L cefpodoxime17 and subcultured onto BrillianceTM agar as
before.17,18 Oxidase-negative presumptive colonies of ESBLPE were defined
as: !, 1–10 cfu; !!, 10–100 cfu; and !!!, 100 cfu. One colony from
each different colony morphology, from each plate of Brilliance agar, was
identified using MALDI-TOF MS (Bruker UK Ltd) and tested for the blaCTX-M
gene using multiplex PCR.19 Full-length gene amplification and sequencing
identified blaCTX-M genotypes (Table 1). A 10lg ertapenem disc was placed
on all selective plates to detect potential carbapenemase-producing
Enterobacteriaceae (CPE).20 Colonies growing in the zone of inhibition were
tested by PCR for CPE genes.21
Data analysis
To estimate the prevalence of ESBLPE colonization for adults living in
England in 2014 we used post-stratification weights based on the 2011 na-
tional census and number of eligible individuals at selected practices. To es-
timate the prevalence for each GP practice and PCT we used sampling
weights based on the numbers of eligible individuals in each group at each
practice. A new variable ‘region of origin’ was derived mainly from ethnic
group and country of birth. Multivariable logistic regression models were
used to control for country of birth and region of origin (if born in the UK)
(Table 2). Based on this preliminary analysis, factors that were associated
with an increased risk of colonization were considered in further analysis.
We also considered the strength of evidence and the number of missing
values, and the evidence from other studies; we did not follow an auto-
mated model selection process. The final multivariable model for coloniza-
tion with CTX-M ESBLPE included country of birth and region of origin
(if born in the UK) as a factor variable with eight categories, the base cat-
egory of which was ‘born in some country not including the UK, India,
Pakistan or Bangladesh (IPB), Sri Lanka, Afghanistan or the Middle East’
(Table 3). From the final model we estimated the adjusted ORs (aORs) for
each risk factor, the percentage of carriers attributable to each risk factor
(for example, travel to India) and, for groups of risk factors (for example,
travel abroad in past year), the population attributable fraction (PAF). The
PAF is dependent on both the aOR and the probability of being exposed to
the factor.
Among participants colonized with CTX-M ESBLPE we calculated the
percentage colonized with a particular blaCTX-M genotype, and the percent-
age belonging to particular ethnic groups among those who were carriers
of a particular blaCTX-M genotype.
Ethics
Approval for the study was obtained from the NRES Committee South West
- Frenchay, Bristol, UK (13/SW/0017). The data we collected from GP prac-
tices were anonymous.
Results
Of 76154 adult individuals registered in 16 GP practices, 58337 were
invited to participate; 3389 (5.8%) expressed interest and were sent
a faeces kit, and 2331 (4.0%) returned a sample. A further 99 individ-
uals invited by general practice receptionists participated, making a
total of 2430 participants. The number of stool specimens received
from participants in each section of the adult population in England,
the number of specimens positive for ESBLPE, and the unweighted
and weighted percentage positive for ESBLPE are shown in Table 2.
The estimated prevalence of colonization with CTX-M ESBLPE
in adults living in England in 2014 was 7.3% (95% CI 5.6%–9.4%).
Of the four PCTs, Heart of Birmingham teaching PCT (234 partici-
pants) had the highest estimated prevalence at 16.0% (95% CI
CTX-M ESBL-producing Enterobacteriaceae prevalence JAC
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10.2%–24.2%) [Newham 612 participants, 12.7% (95% CI 9.1%–
17.4%); Southampton City 740 participants, 9.2% (95% CI 6.1%–
13.7%); and Shropshire County 774 participants, 4.9% (95% CI
3.4%–7.0%)]. There was no evidence that estimated prevalence dif-
fered by age or sex. There were high estimated prevalences for par-
ticipants born in India (136 participants, 28.7% prevalence, 95% CI
18.8%–41.2%), Pakistan (81 participants, 18.6% prevalence, 95% CI
10.5%–30.8%), Bangladesh (34 participants, 23.5% prevalence, 95%
CI 11.8%–41.3%), Sri Lanka (8 participants, 25.0% prevalence, 95%
CI 7.2%–59.0%), Afghanistan (10 participants, 60.0% prevalence,
95% CI 29.7%–84.2%) and the Middle East (18 participants, 15.5%
prevalence, 95% CI 4.7%–40.5%) (Figure 1). The overall estimated
prevalence for those born in the Indian subcontinent (India,
Pakistan, Bangladesh or Sri Lanka) combined (259 participants) was
25.0%, (95% CI 18.5%–32.9%); differences between these four
countries were non-significant (P"0.65). The estimated prevalence
for those born in the UK with an IPB region of origin was 15.7% (52
participants), while for those born in the UK with a UK region of origin
(1459 participants) it was 5.6% (95% CI 4.4%–7.1%, P"0.03).
However there was a low estimated prevalence for those born in
Africa and of the IPB ethnic group (17 participants, 0% prevalence,
95% CI 0%–19.5%).
Overall estimated prevalence of ESBLPE was the same in those
reporting taking any antibiotic in the last year (777 participants,
6.8% prevalence 95% CI 5.1%–8.9%) or not (1427 participants,
6.8% prevalence 95% CI 5.4%–8.6%). None of 48 participants who
reported having taken any co-amoxiclav in the past 12 months
carried ESBLPE (0% prevalence, 95% CI 0%–7.4%, P"0.03).
Estimated prevalence of ESBLPE in the 15 participants who had
taken ciprofloxacin was 9.5%, (95% CI 2.5%–30.1%, P"0.61).
Two other groups with high estimated prevalence were those
who had travelled to South Asia (India, Pakistan, Bangladesh, Sri
Lanka or Nepal) in the last year (140 participants, 38.5% preva-
lence, 95% CI 27.8%–50.5%) and those working as a domestic in a
healthcare setting [8 participants, unweighted prevalence 37.5%,
95% CI 8.5%–75.5% (3/8; 1 black African, CTX-M-15, no travel
abroad; 1 white British, CTX-M-15, travelled to India with partner
for 12 days; 1 Asian Indian, CTX-M-27, travelled to India alone for
42 days)]. If someone else in the participant’s household had been
to India, Bangladesh, the Middle East, the Indian subcontinent or
South East or Pacific Asia, this significantly increased the partici-
pant’s risk for carrying blaCTX-M ESBL. Participants whose
housemates had travelled abroad in the last year to the Indian
subcontinent (India, Pakistan, Bangladesh or Sri Lanka) (120 par-
ticipants, estimated prevalence 22.7%, 95% CI 14.2%–34.1%,
P,0.001), India (83 participants, estimated prevalence 24.9%
95% CI 14.5%–39.2%, P,0.001) and the Middle East (43 partici-
pants, estimated prevalence 16.9%, 95% CI 7.5%–33.6%,
P"0.02) had a higher prevalence. In 1071 of 1234 participants,
both the housemate and the main participant had travelled to the
same country in the past 12 months.
Relative frequency of CTX-M genotypes (Figure 2)
Two hundred and eight participants were found to carry the CTX-M
gene; 184 (88%) by direct culture (25%!, 26%!!, 37%!!!)
and a further 24 (12%) on enrichment; no single participant had
more than one species of bacteria carrying CTX-M. Most isolates
(199) were E. coli, 5 Klebsiella pneumoniae, 4 Enterobacter and 1
Citrobacter. All isolates could be allocated a CTX-M grouping.
Seventy-seven percent of participants with CTX-M ESBLPE (161/
208) were colonized with CTX-M group 1; 25% (53/208) were
colonized with CTX-M group 9; 4% (9/208) were colonized with
both group 1 and group 9; and 1.4% (3/208) were colonized with
CTX-M group 8, 25 or 26. Four isolates from group 1 and one isolate
from group 9 could not be sequenced. The most common geno-
type was blaCTX-M-15 (66%, 134/204) (Figure 2). Two other common
genotypes were blaCTX-M-14 (11%, 23/207) and blaCTX-M-27 (13%,
27/207).
CTX-M genotypes and risk factors
Carriers of blaCTX-M-15 had a similar probability of being of white
ethnicity compared with carriers of other genotypes (62/134, 46%
of blaCTX-M-15 were white; 46/134, 34% Asian IPB; and 26/134, 19%
other ethnicity) and 84/129 (65%) had travelled abroad in the last
year. A carrier of blaCTX-M-27 had a higher chance of being of the
Asian-IPB ethnic group (16/27, 59% Asian IPB; 6/27, 22% white;
5/27, 19% other ethnicity; 16/27, 59% travelled abroad) compared
with carriers of other genotypes. A blaCTX-M-14 carrier had a higher
chance of being of white ethnicity (19/23, 83% white; 2/23, 9%
Asian IPB; 2/23, 9% other ethnicity; 14/23, 61% travelled abroad)
compared with carriers of other genotypes. Carriers of the different
genotypes CTX-M-15, -27 and -14 had a similar chance of having
Table 1. List of PCR and sequencing primers
CTX-M group Name Primer sequence Location
8 and 25/26 50CTXM26 TTG ATT AAC TAC AAC CCC AT CTX-M-26 (313–332)
30CTXM26 GAT ATC ATT CGT CGT ACC AT CTX-M-26 (747–728)
50CTXMF26-1 CTC TGC GCA ATC TGA CGT TG CTX-M-26 (575–594)
50CTXMF26-2 AAG GCG GGC GAT GTT AAT GA CTX-M-26 (18–37)
30CTXMR26-1 GCC AAT CGT ACG GGC AAA TG CTX-M-26 (477–458)
1 ISEcp1 AAA AAT GAT TGA AAG GTG GT ISEcp1 (#149 to#128)
30CTXM-1R ATA CAT CGC GAC GGC TTT CT CTX-M-1 (838–819)
50G1S1 ATG GTT AAA AAA TCA CTG CG CTX-M-15 (1–20)
9 50G9full GAA TAC TGA TGT AAC ACG GAT CTX-M-9 (#40 to#22)
30G9full AGT TAC AGC CCT TCG GCG AT CTX-M-9 (859–878)
McNulty et al.
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travelled abroad in the last year. Of the 199 E. coli, 87% (173/199)
were ST131. ST131 was not significantly more common in CTX-M
carriers who had spent time anywhere abroad in the last year, or in
the Indian subcontinent (India, Pakistan, Bangladesh or Sri Lanka),
compared with those who had not (spent time anywhere abroad
87% ST131 versus not spent time abroad 79%, P"0.17; spent
time abroad in the Indian subcontinent 91% ST131 versus not
spent time in the Indian subcontinent 82%, P"0.17).
Risk factors for colonization with CTX-M ESBLPE
After adjusting for country of birth and region of origin (if born in
the UK) we found no evidence for an independent association be-
tween CTX-M ESBLPE colonization and GP practice, age group, sex,
overall antibiotic use in the past year or hospitalization in the past
year (Table 2). Factors that remained significant after adjusting for
country of birth and region of origin (if born in the UK) and were
therefore considered for inclusion in the final model included: par-
ticipant’s travel abroad, or diarrhoea or hospitalization abroad in
the last year; use of ciprofloxacin or co-amoxiclav; being a domes-
tic healthcare worker; and housemates’ travel abroad (overall and
by country) in the last year. When added to the final multivariable
model, there was no strong evidence that colonization was inde-
pendently associated with either taking antibiotics in the last year
(aOR 0.99, 95% CI 0.7–1.4, P"0.95), hospitalization abroad in the
last year (aOR 2.7, 95% CI 0.8–9.1, P"0.11, 3/12 colonized), diar-
rhoea while abroad in the last year (aOR 1.1, 95% CI 0.6–1.9,
P" 0.84, 16/137 colonized) or travel abroad by a participant’s
housemate in the past year (aOR 1.4, P"0.11, 103/1071 colon-
ized). Use of ciprofloxacin remained a significant risk factor for
ESBLPE-CTX-M in the final model (4/15 ESBLPE positive, aOR 3.2,
P"0.03), whereas co-amoxiclav was protective for presence of
ESBLPE-CTX-M (0/48 ESBLPE positive, aOR 0, P"0.006).
Being born in the Indian subcontinent (India, Pakistan,
Bangladesh or Sri Lanka) was the most important identified risk
factor for faecal colonization (aOR 5.4, 95% CI 3.0–9.7), and we es-
timate it accounted for 23.8% (95% CI 15.9%–30.9%) of people
colonized in England in 2014 (Table 3). Being born in Afghanistan
(aOR 46.0, 95% CI 9.6–218) or the Middle East (aOR 4.7, 95% CI
1.3–17.0) were factors strongly associated with colonization, but
being relatively rare we estimate them to have accounted for rela-
tively few people colonized [2.8% (95% CI 1.3%–4.3%) and 1.1%
(95% CI#0.4% to 2.6%), respectively]. We found no evidence
when tested in the final model that birth in or travel to other coun-
tries including Eastern Europe increased risk of colonization (travel
to Eastern Europe aOR 0.8, P"0.42; born in Eastern Europe aOR
0.5, P"0.38). There was no evidence that being born in the UK
with a UK region of origin was a risk factor for colonization
(aOR 1.3, 95% CI 0.8–2.1, P"0.24); but as there were so many par-
ticipants in this group, we estimate it accounted for 9.9%
(95% CI#7.1% to 24.1%) of people colonized. Being born in the UK
with an IPB region of origin was strongly associated with coloniza-
tion (aOR 3.8, 95% CI 1.5–9.2), and we estimate it accounted for
2.8% (95% CI 0.1%–5.4%) of people colonized. Being born in the
UK with a Caribbean region of origin was almost as strongly associ-
ated with colonization as being born in the UK with an IPB region of
origin (aOR 3.4, 95% CI 1.0–10.9), and we estimate it accounted
for 1.4% (95% CI#0.6% to 3.3%) of people colonized.
Travel to South Asia (India, Pakistan, Bangladesh, Sri Lanka or
Nepal) in the last year was strongly associated with colonization
*IPB = India, Pakistan or Bangladesh 
0 10 20 30 40 50 60 70 80 90
% Prevalence of colonization with CTX-M ESBLPE
Born UK : UK origin
Born UK : Asia-IPB* origin
Born UK : Caribbean origin
Born UK : Other origin
Born India
Born Afghanistan
Born Middle East
Born some other country (incl.
Caribbean)
Born IPB or Sri Lanka
Born Sri Lanka
Born Bangladesh
Born Pakistan
England Overall
Region of origin/origin is derived from the self-declared ethnic group and country of birth 
Figure 1. Prevalence of colonization with CTX-M ESBLPE by country of birth and region of origin if born in the UK (with 95% CI). Adults from the
general population of England in 2014. Dotted line is the estimated 2014 prevalence in England.
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(aOR 2.9, 95% CI 1.8–4.8), and we estimate it accounted for 12.1%
(95% CI 5.9%–17.8%) of people colonized. Travel to Africa, China,
South or Central America, South East or Pacific Asia or Afghanistan
in the last year also increased the risk of colonization (aOR 2.6,
95% CI 1.7–4.1), and we estimate it accounted for 9.9% (95% CI
4.3%–15.1%) of people colonized. Travel to other countries in the
last year put participants at a small increased chance of coloniza-
tion (aOR 1.3, 95% CI 0.9–1.8; P"0.15) and, being relatively com-
mon, we estimate it accounted for 7.9% (95% CI#3.5% to 18.1%)
of people colonized. Working as a domestic in the healthcare set-
ting was strongly associated with colonization (aOR 6.2, 95% CI
1.3–31.0), but, being relatively rare, we estimate it to have ac-
counted for just 1.1% (95% CI#0.2% to 2.3%) of people colonized.
Collectively all risk factors in the final multivariable model ex-
plained 60.4% (95% CI 40.0%–73.8%) of cases.
Only 0.1% of participants (2/2430) were colonized with CPE; nei-
ther was born in the UK, and both had a history of travel to India in
the past year.
Discussion
The 7.3% estimate for the prevalence of faecal colonization with
CTX-M ESBLPE in adults living in England in 2014, and the high esti-
mated prevalence in those born in South Asia (India, Pakistan,
Bangladesh or Sri Lanka) and in those travelling to certain areas
including South Asia, is of concern and has implications for empir-
ical antimicrobial prescribing for suspected infections caused by
Enterobacteriaceae and infection prevention and control
within healthcare in England and beyond. The significantly higher
estimated prevalence (15.7%) in the 52 participants born in the UK
with an IPB region of origin, compared with those born in the
UK with a UK region of origin (1459 participants, estimated preva-
lence 5.6%), is interesting; the higher estimated prevalence may
be due to acquisition during repeated travel to their country of ori-
gin, or from visits by family and friends to or from their country of
origin, during the last year or more than 1 year ago, or acquisition
from relatives in the home.22
Previous studies in the UK
The only previous faecal colonization study of ESBLPE in the UK
(in 2010) showed that Middle Eastern or South Asian (India,
Pakistan, Bangladesh, Sri Lanka or Nepal) patients being investi-
gated for gastrointestinal infections had a significantly higher
prevalence than Europeans.11 Although UK studies estimating
ESBLPE infection rates in hospitalized patients or patients with
urine infections (UTIs) have suggested (similar to this present
study) that rates of ESBLPE infection vary widely between different
areas of the UK23,24 they have not investigated other risk factors.
Previous studies of a general population in Northern
Europe
A 2011 postal study in urban Amsterdam estimated that the over-
all prevalence of ESBLPE faecal colonization was 8.6% and travel
to Asia or Africa (aOR 2.1–2.2) in the last year increased the risk.
Unlike the present or other studies, they found antibiotic use in
the last year and travel to North America (aOR 2.7) were also
Group 1
161, 77%
Group 8*
3, 1.4%
CTX-M-15
CTX-M-1
CTX-M-55
CTX-M-3
CTX-M-32
New?
Not Typed
134 (66%)
9 (4.4%)
2 (1%)
1 (0.5%)
4 (2%)
3 (1.5%)
8 (3.9%)
CTX-M-14:
19/23, 83% White
2/23, 9% Asian IPB
2/23, 9% Other ethnicity
14/23, 61% Travel abroad
CTX-M-27
CTX-M-14
27 (13%)
23 (11%)
CTX-M-9
New?
Not Typed 1 (0.5%)
1 (0.5%)
1 (0.5%)
CTX-M-15:
62/134, 46% White
46/134, 34% Asian IPB
26/134, 19% Other ethnicity
84/129, 65% Travel abroad
CTX-M-27:
6/27, 22% White
16/27, 59% Asian IPB
5/27, 19% Other ethnicity
16/27, 59% Travel abroad
Group 9
53, 24%
As each isolate could have more than one genotype, the relative frequencies for the different genotypes sum to more than 100% of individuals as nine 
individual isolates carried both CTX-M group 1 and group 9 genes
*The three isolates in group 8 were not sequenced
Figure 2. Relative frequency of the blaCTX-M genotypes from 208 individuals, characterizations of these genotypes and risk factors for them.
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risk factors.3 The Amsterdam study found, as in the present study,
that country of origin was important, as having a mother born in
Asia was a risk factor independent of foreign travel (aOR 2.4). In
the present and Amsterdam studies, hospitalization abroad in the
past year led to significantly higher faecal colonization and risk in
the univariable analysis, but neither found hospitalization abroad
significant on multivariable analysis.3 The Amsterdam study did
not investigate travellers’ diarrhoea as a risk factor.3
A 2014/15 general population study in the rural Southern
Netherlands estimated the prevalence of faecal colonization with
ESBL/AmpC Enterobacteriaceae to be 4.5%. This is similar to our esti-
mate for adults living in Shropshire in 2014, which is also rural with al-
most the entire population born in the UK and of UK origin. This study,
like ours, found travel to Africa, Asia and Latin America (aOR 2.9), was
a risk factor for carriage.25 Participants living in close proximity to
mink farms (but not other farms) and keeping cows for a hobby in the
last 5 years (aOR 3.56) had increased risk.25 Despite other studies
showing that contact with broiler farms increased risk in the
Netherlands,26 neither contact with animals, pets or eating meat
(including chicken) increased the risk of ESBLPE colonization in our
study. The risk factor associated with animals may only be evident
when you closely examine particular livestock, which we did not do.
A systematic review of faecal colonization27 with Ambler class A
ESBLPE in healthy individuals between 1992 and 2014 found that
ESBLPE colonization had increased over time and was present
worldwide in 2014. The pooled estimated prevalence was highest
in the West Pacific (46%), followed by South East Asia and Africa
(22%), the Eastern Mediterranean (15%) and Northern Europe
(4%). Factors associated with a higher risk of colonization were
international travel (RR 4.06) and antibiotic use in the previous year
(RR 1.58), but this was a univariate analysis.27 The significant effect
of antibiotic use in that review may not have remained on multi-
variable analysis or may be caused by relatively greater use of
broader spectrum antibiotics (especially quinolones) in countries
outside Northern Europe and in travellers. Interestingly, although
overall antibiotic use was not a significant risk factor in our study,
participants reporting ciprofloxacin use in the past year did have
significantly increased estimated prevalence and this risk re-
mained in the final multivariable model (aOR 3.2, P" 0.03).
However, all four cases who reported taking ciprofloxacin and were
CTX-M ESBLPE positive had other risk factors (all four participants
were of Asian ethnicity, three were hospitalized in the past year
and one travelled to Pakistan). In contrast, reported co-amoxiclav
use in the last year appeared to be protective, as none of these
48 participants was positive for CTX-M ESBLPE (0%, P"0.03). This is
an important and interesting finding that needs further investiga-
tion. Although co-amoxiclav has limited clinical activity against
CTX-M ESBLPE it is possible that there are high enough concentra-
tions in the gut to eliminate faecal carriage. In contrast, ciprofloxa-
cin would be expected to encourage colonization as almost all UK
CTX-M ESBLPE are resistant.28 Only one of the previously published
studies of ESBLPE colonization in the general population reported
estimated prevalence by region of origin, and found birth in Africa,
or parents born in Africa or Asia, to be an important risk factor.3
Previous studies of travellers
Like this study, studies of travellers from other European countries
have identified travel outside Europe, and especially to the Middle
East, Africa and South Asia, to be a risk for ESBLPE faecal coloniza-
tion and acquisition;10,27,29–31 with travel to Southern India being
the greatest risk.10 In several studies, travellers’ diarrhoea and the
use of antimicrobials were independent risk factors for acquiring
ESBLPE, which is not consistent with our own findings.10,27,29–31
However, another 2012 study of travellers from a Swiss travel clinic
to South Asia found length of stay, visiting friends and relatives
and eating ice-cream were risk factors for acquisition of ESBLPE E.
coli; whereas travellers’ diarrhoea was not a risk factor.13 Visiting
friends or relatives is probably a marker of being born in South Asia,
which was a risk factor for colonization in our present study. In
studies like this and ours, which included a larger proportion of
travellers visiting relatives, travellers’ diarrhoea may not be such
an important marker for faecal colonization, as these travellers’
gut microbiome may have already adapted to the South Asian diet
and environmental flora. Although travel abroad by a housemate
was associated with significantly higher carriage, this did not re-
main significant in the final model. Travel abroad by a housemate
was closely correlated with spending time abroad by the partici-
pant themselves (1071/1234); so it is therefore not possible to dis-
tinguish between the effect of this variable and the effect of travel
abroad by the person themselves.
Two longitudinal studies of travellers who were ESBLPE carriers
on return from abroad report the prevalence of carriage 12 months
after returning to be 11.3% and 2.2%, respectively, confirming that
travel abroad more than 1 year ago could be an important factor
to investigate in future studies.10,32 Our questions about travel
abroad were limited to the last year; this omission could be import-
ant for travellers who travel repeatedly to areas with higher preva-
lence of CTX-M ESBLPE and poor hygiene or sanitation, for example
participants born in the UK of IPB or Caribbean origin who may be
more likely to repeatedly visit family and friends. This would help
to explain the higher carriage and risk conferred by being UK-born
but of IPB or Caribbean origin.
Unlike the 2016 systematic review we did not find that esti-
mated prevalence of CTX-M ESBLPE was significantly higher in
those born in or travelling to Eastern Europe (15/249 participants
CTX-M ESBLPE positive, aOR 0.9, 95% CI 0.5–1.6, P"0.77).27 This
may be because sanitation facilities in these countries are better
than on the Indian subcontinent (India, Pakistan, Bangladesh or Sri
Lanka) so that acquisition in these countries is less common.
In our study the estimated prevalence of CTX-M ESBLPE among
those working as domestics in healthcare was 37.5% (3/8 partici-
pants, 95% CI 8.5%–75.5%). The risk factor was found to be inde-
pendently associated with an increased risk of colonization; and
these eight participants were not similarly exposed to any other
particular risk factor. Domestics in healthcare settings may be put
at increased risk through their work cleaning toilet facilities; cer-
tainly studies suggest that environmental acquisition may be re-
sponsible for the spread of ESBLPE.13 Transmission of ESBLPE
occurs between patients in healthcare settings and staff do not al-
ways adhere to infection control guidelines.33
As in other studies3,11,24,34 the dominant CTX-M ESBLPE geno-
type was blaCTX-M-15, making up 66% of carriers of CTX-M ESBLPE.
Interestingly we saw very few carriers of blaCTX-M-1, typically associ-
ated with European farm animals,35,36 suggesting little acquisition
from these sources. This is supported by our lack of evidence that
either having a meat diet or working with animal livestock were risk
factors for CTX-M ESBLPE colonization. A quarter of carriers in our
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study carried a genotype belonging to CTX-M group 9, similar to the
previous UK study of diagnostic faeces samples in Birmingham.11
blaCTX-M-27 made up half of the group 9 CTX-Ms in our study, but
was not found in the Birmingham study; in contrast, we found only
one blaCTX-M-9, whereas this constituted 74% of group 9 in the
Birmingham study.11 blaCTX-M-27, which is part of group 9, is a vari-
ant of blaCTX-M-14 that has been reported both from the Far East
and from Europe, and in the UK has been reported at a low fre-
quency from food animals, notably dairy cattle.37 In our study, car-
riers of blaCTX-M-27 were mainly from the Asian-IPB ethnic group
(59%), whereas carriers of blaCTX-M-14 were mainly from the white
ethnic group (83%); this variation by ethnicity warrants further in-
vestigation. In a Spanish study38, CTX-M-14-producing E. coli were
mainly isolated from community UTIs; this was also found in a
Welsh study, where 83% of the CTX-M-14 genotype were commu-
nity acquired39 and they were more common in rural areas.40 CTX-
M-14 E. coli may be indigenous in the UK community, possibly
acquired from cattle.41 Consistent with other work, we found no
group 2 isolates.1
The present study shows that the ST131 clone was the most
prevalent among the isolated E. coli demonstrating that the spread
of CTX-M-15 in the UK may be due to this clone. Our results indicate
that being born in or travel to the Indian subcontinent (India,
Pakistan, Bangladesh or Sri Lanka) was the biggest overall risk fac-
tor, but in the IPB countries the ST131 clone is uncommon.42,43 This
may help us to further explore CTX-M ESBLPE originating in the UK.
As no data exist on the frequency of community colonization of
CPE in the UK, we used our study to gain some insight into their
prevalence. Our culture methods, whilst potentially missing some
OXA-type carbapenemases, are recognized reference laboratory
methods.20 Like other European studies, we found a low incidence of
CPE (0.1%) in England in 2014;44,45 the two positive participants (one
Asian woman with E. coli OXA-48 with CTX-M group 9, and one UK
man with E. coli NDM-1 with CTX-M-15) had both travelled to South
Asia (India, Pakistan, Bangladesh, Sri Lanka or Nepal). This represents
a potential route for the introduction and future spread of CPE.
Strengths
This is the first study to estimate the prevalence of colonization
with CTX-M ESBLPE in the UK general population. We invited a strati-
fied random sample of individuals from the general population
from GP patient lists rather than selecting patients who had given
diagnostic faecal samples or returning travellers who are unrepre-
sentative of the general population. An added value of this study is
the specific focus on ethnicity and the oversampling to retrieve suf-
ficient data in ethnic minority groups, which enabled us to achieve
sufficient power to identify some ethnicities and some countries of
birth as risk factors. The questionnaires that were returned were
well completed and allowed us to investigate a broad range of po-
tential independent risk factors for CTX-M ESBLPE colonization.
Rather than use swabs, we used faecal samples that increase sensi-
tivity of detection of ESBLPE by 10%17,46 and enrichment, which
increased our sensitivity of isolating CTX-M ESBLPE by 12%.17
Limitations
We only sought CTX-M ESBLPE (and not ESBLPE carrying the other
b-lactamase genes blaTEM, blaOXA and blaSHV) as CTX-Ms still
constitute more than 90% of ESBLPE genotypes and cause more
ESBLPE infections than any other type of ESBLPE worldwide.3,47,48
We have not examined the genetic context of blaCTX-M, which
would have given an insight into its linkage to IS elements.
However, this would be unlikely to impact on the control of ESBLPE
transmission. For those exposed to a relatively rare risk factor, the
sample size was small and the CI was wide.
We did not ask about the characteristics of the housemate who
travelled or their relationship to the participant, and housemate
travel did not remain a significant risk in the final multivariable
model (P"0.11). However, it was not our intention to study trans-
mission. In future studies it would be interesting to confirm
whether housemates usually travelled to the same countries with
the participant or at a different time. Many cases of CTX-M faecal
colonization may be unexplainable by any risk factor we could con-
ceivably have collected data on; so, it is possible we have investi-
gated all the important risk factors. However, it is also possible that
some cases could be explained by a risk factor that we did not
have sufficient power to detect or we did not ask about. Questions
about travel abroad and about antibiotic use were limited to the
last year, so this study was not able to investigate whether travel
abroad more than a year earlier or antibiotic use more than a year
earlier are risk factors for colonization. Furthermore we did not col-
lect data on the use of proton-pump inhibitors, found to be a risk
factor for faecal carriage in the Amsterdam 2011 community
study (aOR 1.9)3 and the rural study.25 Since CTX-M ESBLPE are
now widely established in the English general population we were
not surprised to find that many cases were not directly attributable
to travel abroad in the last year.
Most of our prevalence estimates come from a weighted ana-
lysis that weighted participants by ethnic group, age group and
sex. Should our participants be unrepresentative in respect of any
other variable then prevalence estimates for the general popula-
tion could be biased. The risk of such a bias is compounded by the
low response rate (4%) and variation in response rate in the differ-
ent groups.
Implications
Faecal colonization with ESBLPE usually precedes an ESBLPE infec-
tion when it occurs7,8 so we believe that this study, showing CTX-M
ESBLPE to be established in the general population of England and
the prevalence of colonization to be considerably higher among
some sections of the general population, has implications for
empirical prescribing for all infections typically caused by
Enterobacteriaceae, and that antimicrobial guidance should re-
flect our findings.49 The population that is most relevant to any
conclusions about empirical antibiotic prescribing is the population
of those who have infections likely caused by Enterobacteriaceae
and are seen by clinicians. We haven’t studied this population but
we believe that a high prevalence estimate for a section of the
general population can be used to inform on the likely prevalence
of those from the same section of the general population who
seek treatment for infections likely caused by Enterobacteriaceae.
When selecting empirical treatment for uncomplicated UTI
we suggest that clinicians should consider the risk of ESBLPE,
noting recent travel, country of birth and region of origin,
especially South Asia (India, Pakistan, Bangladesh, Sri Lanka or
Nepal). Nitrofurantoin, which has greater activity against ESBLPE,
CTX-M ESBL-producing Enterobacteriaceae prevalence JAC
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is preferable to trimethoprim as an empirical agent in most cases
of acute uncomplicated UTI.49 Although nitrofurantoin will still be
appropriate for most patients with acute uncomplicated UTI, in pa-
tients belonging to a section of the population that has a particu-
larly high risk of ESBLPE carriage it may be preferable to obtain
microbiology specimens before starting antibiotics. This might in-
clude those born in South Asia and in patients who have travelled
to South Asia in the last year. Empirical antimicrobials prescribed
for ‘sepsis’50 should always include an antimicrobial agent that
treats ESBLPE.51
Previous studies of the length of faecal colonization with
ESBLPE have been in patients who have attended a travel clinic
and have acquired colonization abroad. There is wide variation in
the estimates of the percentage still colonized, from 4.8%52 to
14.3%10 of travellers with faecal ESBLPE colonization at 6 months,
and from 2.2%52 to 11.3%10 at 12 months. We need to understand
the length of carriage and transmission in the general population,
which may be different; this would be best investigated in a longi-
tudinal study in a typical population. Prospective or case–control
studies designed to look at the risk of UTI or future infections in
those with ESBLPE faecal colonization are needed. To improve our
understanding of evolving risk groups for ESBLPE infections, we
suggest enhanced or periodic antimicrobial resistance surveillance
should be extended to patients with uncomplicated infections
(to reduce spectrum bias),6 and data collection should include eth-
nic group, age and sex of the patient. If feasible to do so, we also
suggest collecting: country of birth, recent travel history, ethnic
origins, occupation and use of antibiotics and antacids in the
last year.
A study of healthcare domestics’ colonization with ESBLPE com-
pared with other healthcare workers, and possibly patients, is
needed as their numbers in our study were small, and there are
large numbers of domestics working in healthcare with the poten-
tial to transfer ESBLPE. Additionally, domestics receive less training
about infection prevention and control than other healthcare
workers, as they have no direct role in hands-on patient care.
According to our results the prevalence of CPE in the general
population is still very low, and therefore efforts to reduce UK
healthcare transmission of CPE are worthwhile and could help to
delay the inevitable expansion of these genes into the general
population.
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